Gd-enhanced MRI after therapeutic ferumoxytol for iron deficiency anemia - An in-vitro study for optimal contrast timing and dose determination.

Therapeutic ferumoxytol injections can confound subsequently performed magnetic resonance imaging using gadolinium based contrast agents due to its superparamagnetic effects. In this in vitro study, we image various concentrations of ferumoxytol and gadolinium to determine concentration of ferumoxytol which will not affect arterial enhancement in subsequent contrast enhanced scans. Our images demonstrate that significant enhancement can be seen after single dose gadolinium enhanced scans two half-lives with initial ferumoxytol concentration being 300 microgram/ml. Even after one half-life, significant enhancement can be seen with double or triple dosing of gadolinium based contrast agents.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.